A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was: Does repeat thymectomy improve symptoms in patients with refractory myasthenia gravis after thymectomy? A total of 189 papers were found using the reported search, of which seven represented the best evidence to answer the clinical question. The outcome measures included operative mortality and morbidity, as well as long-term remission rate. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. All the studies were small (4-21 patients), retrospective, single institutional case series. There was considerable heterogeneity in the studies. The interval between the first and second operation ranged from less than a year to over 10 years. The operative approach of the initial operation included transcervical, trans-sternal and substernal approaches. The maximal medical therapy received by the patients prior to reoperation varied from anticholinesterase alone to cytotoxic therapy and regular plasmapheresis. The severity of symptoms ranged from Osserman Class IIa to V. The operative approach to re-thymectomy included resternotomy, thoracoscopy and a combination of both. There was no perioperative mortality. One study reported injury to the innominate vein at resternotomy in 3 (14.3%) patients. One study reported myasthenic crisis in 2 patients in the postoperative period. Only one study reported complete remission in 2 patients. In general, however, 52-95% of patients reported some improvement. There was no consistent, objective measure of improvement in these studies. We conclude that repeat thymectomy for patients with refractory myasthenia gravis after previous thymectomy is safe especially for patients whose first procedure was transcervical. Complete remissions are rare but, in these small series, 60-70% of patients report improvement. Clinical improvement appears to be associated with the presence of residual thymic tissue at the second operation, but these cannot be reliably identified on preoperative imaging. Patient selection remains driven by symptoms.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
A 30-year old female was referred to you with myasthenia gravis (MG) who underwent transcervical thymectomy 5 years earlier.
She had Myasthenia Gravis Foundation of America (MGFA) Class IIIb symptoms which improved following surgery to Class IIb symptoms, but she recently required escalation of her medication. Computed tomography (CT) showed no obvious thymic tissue. You were asked to perform a re-thymectomy to ensure that all thymic remnants were removed. You remember being taught that more than a third of myasthenic patients do not benefit from a thymectomy; you find it difficult to believe that over a third of patients would have had incomplete resection. You then question whether there is a role for re-thymectomy in patients who failed to respond the first time. You resolve to check the literature yourself. 
Continued
SEARCH OUTCOME
One hundred and eighty-nine papers were found using the reported search. From these, seven papers were identified which provided the best evidence to answer the question. These are presented in Table 1 .
RESULTS
Masaoka et al. [2] performed trans-sternal extended re-thymectomy in 6 patients who remained with Osserman Class II symptoms after previous transcervical thymectomy. They found thymic remnants beneath the left brachiocephalic vein in all cases. Four (67%) patients improved within a short median follow-up of 10.5 months, although medication requirements and degree of improvement were not reported.
Miller et al. [3] in 1991 reported trans-sternal re-thymectomy in 6 patients with severe myasthenia gravis despite previous thymectomy (4 trans-sternal, 1 transcervical and 1 substernal). All were on maximal medical therapy and 5 required long-term maintenance plasma exchange. No postoperative complications were reported. There was no complete remission after 6 years, but there was a substantial reduction in the medication dosage and plasma exchange cycles, while cytotoxic medication was discontinued in 3 patients.
Rosenberg et al. [4] reported trans-sternal re-thymectomy in 13 patients with persistent symptoms after previous transcervical thymectomy (7 partial recovery, 5 no improvement and 1 worse symptoms) and evidence of residual thymus on pneumomediastinography. Two patients were lost to follow-up. There were no complete remissions at a median follow-up of 11 months, but 7 (64%) patients reported improvement and 5 were on reduced medication.
Henze et al. [5] reported trans-sternal re-thymectomy in 20 patients with generalized, disabling symptoms, which did not improve after transcervical thymectomy after a mean of 6.5 years. While preoperative imaging failed to demonstrate thymic remnants, at operation all had residual thymic tissue and 18 were intact encapsulated thymic lobes. This suggested that the primary operation was incomplete. There was no mortality. At a mean follow-up of 15 months, 19 (95%) patients improved, mean disability score fell (8.2 vs 4.9, P < 0.001), anticholinesterase dose reduced 67% (P < 0.01) and medical immunosuppression was discontinued in 6 of 11 patients and reduced in 4.
Mineo et al. [6] described re-thymectomy using the videoassisted thoracoscopic surgery (VATS) approach in 1998. He reported 4 patients with severe myasthenia gravis on maximal medical therapy (including 3 on regular plasma exchanges) who did not improve after a previous thymectomy (3 transcervical and 1 trans-sternal). In none was there evidence of residual thymic tissue on CT/magnetic resonance imaging (MRI). There was no mortality or major morbidity. There were no complete remissions, but 2 patients did not need further plasma exchange, and 3 had improvement in their Osserman class.
Pompeo et al. [7] updated this series to 8 patients in 2000. There were no deaths, but 2 patients required reintubation for myasthenic crisis. After a mean follow-up of 28.3 months, there was no complete remission, but 6 (75%) patients improved at least one Osserman class and all Class IV patients improved. The mean prednisolone dose reduced from 43 to 20 mg (P = 0.03), but pyridostigmine and azathioprine doses or plasma exchange frequency did not change significantly. All the 5 patients who had gross thymic tissue removed improved.
Zielinśki et al. [8] described resternotomy re-thymectomy in 21 patients with a mean Osserman class of 3.52 using a novel video-assisted re-sternotomy technique. Only 14 (67%) patients received steroids, suggesting that they were not on maximal medical therapy. In 4 (19%) patients, no thymic tissue was found. There were 3 (14.3%) cases of injury to the innominate vein requiring repair, but no mortality or respiratory failure requiring ventilation. Seventeen patients with a follow-up of over a year, a mean follow-up of 3.4 years, were analysed. Two (11.8%) achieved complete remission, 9 (52.9) showed improvement and none showed deterioration. Six (50%) of the 12 patients on steroids or immunosuppressive medication preoperatively were able to discontinue them.
CLINICAL BOTTOM LINE
Repeat thymectomy for patients with refractory myasthenia gravis after previous thymectomy is safe especially for patients whose first procedure was transcervical. Complete remissions are rare, but 60-70% patients report improvement. Clinical improvement appears to be associated with the presence of thymic tissue, but these cannot be reliably identified on preoperative imaging. Patient selection remains driven by symptoms.
